Linked e-resources
Details
Table of Contents
Biographies; Contents; Editors; Contributors; Chapter 1: Overview ofßType 2 Diabetes; 1.1 Epidemiology andßGlobal Disease Burden; 1.2 Diagnostic Criteria forßDiabetes; 1.3 Glucose Homeostasis; 1.4 Pathogenesis ofßType 2 Diabetes; 1.5 Risk Factors forßtheßDevelopment ofßDiabetes; 1.6 Clinical Features ofßDiabetes; 1.7 Complications ofßDiabetes; References; Chapter 2: SGLT2 Inhibitors forßTreating Diabetes; 2.1 Mode ofßAction andßClinical Pharmacology; 2.2 Drug Development andßMajor Clinical Trials; 2.2.1 Phlorizin; 2.2.2 Glycemic Effects ofßDapagliflozin.
2.2.3 Glycemic Effects ofßCanagliflozin2.2.4 Glycemic Effects ofßEmpagliflozin; 2.2.5 Glycemic Effects ofßSGLT2 Inhibitors: Where Are WeßNow?; 2.3 Effects ofßSGLT2 Inhibitors onßBody Weight; 2.4 Effects ofßSGLT Inhibitors onßBlood Pressure; 2.5 Adverse Effects andßSafety; 2.5.1 Hypoglycemia withßSGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects ofßSGLT2 Inhibitors onßLipids; 2.5.5 Effects onßRenal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines forßtheßTreatment ofßType 2 Diabetes Mellitus; 3.1 Introduction.
3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association andßEuropean Association forßtheßStudy ofßDiabetes Position Statement; 3.3.1 Update toßtheßJoint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines inßtheßUK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors inßSpecial Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors inßPatients withßCardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials withßOther SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors inßPatients withßChronic Kidney Disease.
4.3.1 Cohort Analysis ofßPatients Treated withßCanagliflozin4.3.2 Renoprotective Aspects ofßSGLT2 Inhibitors; 4.3.3 Renal Outcome Studies withßSGLT2 Inhibitors; 4.4 SGLT2 Inhibitors inßOlder Patients withßType 2 Diabetes; 4.4.1 Dapagliflozin inßOlder Patients withßType 2 Diabetes; 4.4.2 Canagliflozin inßOlder Patients withßType 2 Diabetes; 4.5 SGLT2 Inhibitors inßType 1 Diabetes; 4.5.1 Empagliflozin inßType 1 Diabetes; 4.5.2 Dapaglifozin inßType 1 Diabetes; 4.5.3 Sotagliflozin inßType 1 Diabetes; 4.5.4 Future Prospects inßType 1 Diabetes; References.
2.2.3 Glycemic Effects ofßCanagliflozin2.2.4 Glycemic Effects ofßEmpagliflozin; 2.2.5 Glycemic Effects ofßSGLT2 Inhibitors: Where Are WeßNow?; 2.3 Effects ofßSGLT2 Inhibitors onßBody Weight; 2.4 Effects ofßSGLT Inhibitors onßBlood Pressure; 2.5 Adverse Effects andßSafety; 2.5.1 Hypoglycemia withßSGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects ofßSGLT2 Inhibitors onßLipids; 2.5.5 Effects onßRenal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines forßtheßTreatment ofßType 2 Diabetes Mellitus; 3.1 Introduction.
3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association andßEuropean Association forßtheßStudy ofßDiabetes Position Statement; 3.3.1 Update toßtheßJoint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines inßtheßUK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors inßSpecial Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors inßPatients withßCardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials withßOther SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors inßPatients withßChronic Kidney Disease.
4.3.1 Cohort Analysis ofßPatients Treated withßCanagliflozin4.3.2 Renoprotective Aspects ofßSGLT2 Inhibitors; 4.3.3 Renal Outcome Studies withßSGLT2 Inhibitors; 4.4 SGLT2 Inhibitors inßOlder Patients withßType 2 Diabetes; 4.4.1 Dapagliflozin inßOlder Patients withßType 2 Diabetes; 4.4.2 Canagliflozin inßOlder Patients withßType 2 Diabetes; 4.5 SGLT2 Inhibitors inßType 1 Diabetes; 4.5.1 Empagliflozin inßType 1 Diabetes; 4.5.2 Dapaglifozin inßType 1 Diabetes; 4.5.3 Sotagliflozin inßType 1 Diabetes; 4.5.4 Future Prospects inßType 1 Diabetes; References.